Table of Contents Author Guidelines Submit a Manuscript
Infectious Diseases in Obstetrics and Gynecology
Volume 2011 (2011), Article ID 429403, 10 pages
http://dx.doi.org/10.1155/2011/429403
Review Article

Multipurpose Prevention Technologies: Biomedical Tools to Prevent HIV-1, HSV-2, and Unintended Pregnancies

CONRAD Clinical Research Center, Eastern Virginia Medical School, 601 Colley Avenue, Norfolk, VA 23507, USA

Received 2 May 2011; Accepted 15 June 2011

Academic Editor: Maura K. Whiteman

Copyright © 2011 Andrea Ries Thurman et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. A. B. Stone, “HIV topical microbicides: the current development strategy is fully justified,” American Journal of Public Health, vol. 94, no. 11, pp. 1845–1847, 2004. View at Google Scholar · View at Scopus
  2. World Health Organization U, UNFPA and the World Bank. Maternal Mortality in 2005: Estimates developed by WHO, UNICEF, UNFPA and the World Bank. 2007.
  3. S. Singh, D. Wulf, R. Hussain, A. Bankole, G. Sedgh, and G. Institute, Abortion Worldwide: A Decade of Uneven Progress, Guttmacher Institute, New York, NY, USA, 2009.
  4. UN AIDS World Health Organization, 09 AIDS Epidemic Update, 2009, http://data.unaids.org/pub/Report/2009/JC1700_Epi_Update_2009_en.pdf.
  5. UN AIDS World Health Organization, 09 AIDS Epidemic Update. Geneva, Switzerland, 2009.
  6. District of Columbia Department of Health, 2008, http://dchealth.dc.gov/doh/frames.asp?doc=/doh/lib/doh/pdf/dc_hiv-aids_2008_updatereport.pdf.
  7. M. C. Boily, R. F. Baggaley, L. Wang et al., “Heterosexual risk of HIV-1 infection per sexual act: systematic review and meta-analysis of observational studies,” The Lancet Infectious Diseases, vol. 9, no. 2, pp. 118–129, 2009. View at Publisher · View at Google Scholar · View at Scopus
  8. J. H. Van de Wijgert, C. S. Morrison, J. Brown et al., “Disentangling contributions of reproductive tract infections to hiv acquisition in African women,” Sexually Transmitted Diseases, vol. 36, no. 6, pp. 357–364, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  9. J. H. van de Wijgert, Z. M. Chirenje, V. Iliff et al., “Effect of intravaginal practices on the vaginal and cervical mucosa of Zimbabwean women,” Journal of Acquired Immune Deficiency Syndromes, vol. 24, no. 1, pp. 62–67, 2000. View at Google Scholar · View at Scopus
  10. M. Laga, A. Manoka, M. Kivuvu et al., “Non-ulcerative sexually transmitted diseases as risk factors for HIV-1 transmission in women: results from a cohort study,” AIDS, vol. 7, no. 1, pp. 95–102, 1993. View at Google Scholar · View at Scopus
  11. B. Van Der Pol, C. Kwok, B. Pierre-Louis et al., “Trichomonas vaginalis infection and human immunodeficiency virus acquisition in African women,” Journal of Infectious Diseases, vol. 197, no. 4, pp. 548–554, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  12. R. S. McClelland, L. Sangare, W. M. Hassan et al., “Infection with Trichomonas vaginalis increases the risk of HIV-1 acquisition,” Journal of Infectious Diseases, vol. 195, no. 5, pp. 698–702, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  13. H. L. Martin, B. A. Richardson, P. M. Nyange et al., “Vaginal lactobacilli, microbial flora, and risk of human immunodeficiency virus type 1 and sexually transmitted disease acquisition,” Journal of Infectious Diseases, vol. 180, no. 6, pp. 1863–1868, 1999. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  14. L. Myer, L. Kuhn, Z. A. Stein, T. C. Wright Jr., and L. Denny, “Intravaginal practices, bacterial vaginosis, and women's susceptibility to HIV infection: epidemiological evidence and biological mechanisms,” The Lancet Infectious Diseases, vol. 5, no. 12, pp. 786–794, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  15. L. Myer, L. Denny, R. Telerant, M. Souza, T. C. Wright Jr., and L. Kuhn, “Bacterial vaginosis and susceptibility to HIV infection in South African women: a nested case-control study,” Journal of Infectious Diseases, vol. 192, no. 8, pp. 1372–1380, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  16. T. E. Taha, D. R. Hoover, G. A. Dallabetta et al., “Bacterial vaginosis and disturbances of vaginal flora: association with increased acquisition of HIV,” AIDS, vol. 12, no. 13, pp. 1699–1706, 1998. View at Publisher · View at Google Scholar · View at Scopus
  17. J. H. van de Wijgert, C. S. Morrison, P. G. A. Cornelisse et al., “Bacterial vaginosis and vaginal yeast, but not vaginal cleansing, increase HIV-1 acquisition in African women,” Journal of Acquired Immune Deficiency Syndromes, vol. 48, no. 2, pp. 203–210, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  18. J. R. Lama, A. Lucchetti, L. Suarez et al., “Association of herpes simplex virus type 2 infection and syphilis with human immunodeficiency virus infection among men who have sex with men in Peru,” Journal of Infectious Diseases, vol. 194, no. 10, pp. 1459–1466, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  19. A. Rebbapragada, C. Wachihi, C. Pettengell et al., “Negative mucosal synergy between Herpes simplex type 2 and HIV in the female genital tract,” AIDS, vol. 21, no. 5, pp. 589–598, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  20. P. Van de Perre, M. Segondy, V. Foulongne et al., “Herpes simplex virus and HIV-1: deciphering viral synergy,” The Lancet Infectious Diseases, vol. 8, no. 8, pp. 490–497, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  21. A. R. Thurman and G. F. Doncel, “Innate immunity and inflammatory response to Trichomonas vaginalis and bacterial vaginosis: relationship to HIV acquisition,” American Journal of Reproductive Immunology, vol. 65, no. 2, pp. 89–98, 2010. View at Publisher · View at Google Scholar · View at PubMed
  22. M. F. Gallo, D. A. Grimes, L. M. Lopez, and K. F. Schulz, “Non-latex versus latex male condoms for contraception,” Cochrane Database of Systematic Reviews, no. 1, Article ID CD003550, 2006. View at Google Scholar · View at Scopus
  23. K. R. Davis and S. C. Weller, “The effectiveness of condoms in reducing heterosexual transmission of HIV,” Family Planning Perspectives, vol. 31, no. 6, pp. 272–279, 1999. View at Google Scholar · View at Scopus
  24. D. Mansour, P. Inki, and K. Gemzell-Danielsson, “Efficacy of contraceptive methods: a review of the literature,” European Journal of Contraception and Reproductive Health Care, vol. 15, no. 1, pp. 4–16, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  25. E. L. Gollub, “Choice is empowering: getting strategic about preventing HIV infection in women,” International Family Planning Perspectives, vol. 32, no. 4, pp. 209–212, 2006. View at Publisher · View at Google Scholar · View at Scopus
  26. United States Navy. Sexual Health and Responsibility Program. 2010, http://www.nmcphc.med.navy.mil/downloads/sexual_health/condomaccess.pdf.
  27. A. Treerutkuarkul, “Free condoms at gay nightspots,” The Bangkok Post, 2011. View at Google Scholar
  28. J. Trussell, K. Sturgen, J. Strickler, and R. Dominik, “Comparative contraceptive efficacy of the female condom and other barrier methods,” Family Planning Perspectives, vol. 26, no. 2, pp. 66–72, 1994. View at Google Scholar · View at Scopus
  29. G. Farr, H. Gabelnick, K. Sturgen, and L. Dorflinger, “Contraceptive efficacy and acceptability of the female condom,” American Journal of Public Health, vol. 84, no. 12, pp. 1960–1964, 1994. View at Google Scholar · View at Scopus
  30. P. P. French, M. Latka, E. L. Gollub, C. Rogers, D. R. Hoover, and Z. A. Stein, “Use-effectiveness of the female versus male condom in preventing sexually transmitted disease in women,” Sexually Transmitted Diseases, vol. 30, no. 5, pp. 433–439, 2003. View at Publisher · View at Google Scholar · View at Scopus
  31. Z. Mukandavire and W. Garira, “Sex-structured HIV/AIDS model to analyse the effects of condom use with application to Zimbabwe,” Journal of Mathematical Biology, vol. 54, no. 5, pp. 669–699, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at MathSciNet · View at Scopus
  32. D. W. Dowdy, M. D. Sweat, and D. R. Holtgrave, “Country-wide distribution of the nitrile female condom (FC2) in Brazil and South Africa: a cost-effectiveness analysis,” AIDS, vol. 20, no. 16, pp. 2091–2098, 2006. View at Google Scholar · View at Scopus
  33. M. Warren and A. Philpott, “Expanding safer sex options: introducing the female condom into national programmes,” Reproductive Health Matters, vol. 11, no. 21, pp. 130–139, 2003. View at Publisher · View at Google Scholar · View at Scopus
  34. R. A. Hatcher, J. Trussell, A. L. Nelson, W. Cates, F. H. Stewart, and D. Kowal, Eds., Contraceptive Technology, Ardent Media, New York, NY, USA, 2007.
  35. World Health Organization, The Safety and Feasibility of Female Condom Reuse: Report of a WHO Consultation, World Health Organization, Geneva, Switzerland, 2002.
  36. P. S. Coffey, M. Kilbourne-Brook, G. Austin, Y. Seamans, and J. Cohen, “Short-term acceptability of the PATH Woman's condom among couples at three sites,” Contraception, vol. 73, no. 6, pp. 588–593, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  37. J. L. Schwartz, K. Barnhart, M. D. Creinin et al., “Comparative crossover study of the PATH Woman's condom and the FC female condom,” Contraception, vol. 78, no. 6, pp. 465–473, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  38. B. K. Patterson, A. Landay, J. Andersson et al., “Repertoire of chemokine receptor expression in the female genital tract: implications for human immunodeficiency virus transmission,” American Journal of Pathology, vol. 153, no. 2, pp. 481–490, 1998. View at Google Scholar · View at Scopus
  39. Q. Li, J. D. Estes, P. M. Schlievert et al., “Glycerol monolaurate prevents mucosal SIV transmission,” Nature, vol. 458, no. 7241, pp. 1034–1038, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  40. T. R. Moench, T. Chipato, and N. S. Padian, “Preventing disease by protecting the cervix: the unexplored promise of internal vaginal barrier devices,” AIDS, vol. 15, no. 13, pp. 1595–1602, 2001. View at Publisher · View at Google Scholar · View at Scopus
  41. L. Cook, K. Nanda, and D. Grimes, “Diaphragm versus diaphragm with spermicides for contraception,” Cochrane Database of Systematic Reviews, no. 2, p. CD002031, 2001. View at Google Scholar · View at Scopus
  42. M. J. Rosenberg, A. J. Davidson, J. H. Chen, F. N. Judson, and J. M. Douglas, “Barrier contraceptives and sexually transmitted diseases in women: a comparison of female-dependent methods and condoms,” American Journal of Public Health, vol. 82, no. 5, pp. 669–674, 1992. View at Google Scholar · View at Scopus
  43. J. Kelaghan, G. L. Rubin, H. W. Ory, and P. M. Layde, “Barrier-method contraceptives and pelvic inflammatory disease,” Journal of the American Medical Association, vol. 248, no. 2, pp. 184–187, 1982. View at Publisher · View at Google Scholar · View at Scopus
  44. A. M. Minnis and N. S. Padian, “Effectiveness of female controlled barrier methods in preventing sexually transmitted infections and HIV: current evidence and future research directions,” Sexually Transmitted Infections, vol. 81, no. 3, pp. 193–200, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  45. N. S. Padian, A. van der Straten, G. Ramjee et al., “Diaphragm and lubricant gel for prevention of HIV acquisition in southern African women: a randomised controlled trial,” The Lancet, vol. 370, no. 9583, pp. 251–261, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  46. G. Ramjee, A. van der Straten, T. Chipato et al., “The diaphragm and lubricant gel for prevention of cervical sexually transmitted infections: results of a randomized controlled trial,” PLoS One, vol. 3, no. 10, Article ID e3488, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  47. J. L. Schwartz, S. A. Ballagh, M. D. Creinin et al., “SILCS diaphragm: postcoital testing of a new single-size contraceptive device,” Contraception, vol. 78, no. 3, pp. 237–244, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  48. P. S. Coffey, M. Kilbourne-Brook, V. Brache, and L. Cochon, “Comparative acceptability of the SILCS and Ortho ALL-FLEX diaphragms among couples in the Dominican Republic,” Contraception, vol. 78, no. 5, pp. 418–423, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  49. M. Malkovsky, A. Newell, and A. G. Dalgleish, “Inactivation of HIV by nonoxynol-9,” The Lancet, vol. 1, no. 8586, p. 645, 1988. View at Google Scholar · View at Scopus
  50. B. Polsky, P. A. Baron, J. W. Gold, J. L. Smith, R. H. Jensen, and D. Armstrong, “In vitro inactivation of HIV-1 by contraceptive sponge containing nonoxynol-9,” The Lancet, vol. 1, no. 8600, p. 1456, 1988. View at Google Scholar · View at Scopus
  51. C. Harrison and E. Chantler, “The effect of nonoxynol-9 and chlorhexidine on HIV and sperm in vitro,” International Journal of STD and AIDS, vol. 9, no. 2, pp. 92–97, 1998. View at Publisher · View at Google Scholar · View at Scopus
  52. D. R. Hicks, L. S. Martin, J. P. Getchell, J. L. Heath, D. P. Francis, J. S. McDougal et al., “Inactivation of HTLV-III/LAV-infected cultures of normal human lymphocytes by nonoxynol-9 in vitro,” The Lancet, vol. 2, no. 8469-8470, pp. 1422–1423, 1985. View at Google Scholar
  53. R. Jennings and A. Clegg, “The inhibitory effect of spermicidal agents on replication of HSV-2 and HIV-1 in-vitro,” Journal of Antimicrobial Chemotherapy, vol. 32, no. 1, pp. 71–82, 1993. View at Google Scholar · View at Scopus
  54. P. J. Feldblum, A. Adeiga, R. Bakare et al., “SAVVY vaginal gel (C31G) for prevention of HIV infection: a randomized controlled trial in Nigeria,” PLoS One, vol. 3, no. 1, Article ID e1474, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  55. L. Van Damme, G. Ramjee, M. Alary et al., “Effectiveness of COL-1492, a nonoxynol-9 vaginal gel, on HIV-1 transmission in female sex workers: a randomised controlled trial,” The Lancet, vol. 360, no. 9338, pp. 971–977, 2002. View at Publisher · View at Google Scholar · View at Scopus
  56. L. Peterson, K. Nanda, B. K. Opoku et al., “SAVVY (C31G) gel for prevention of HIV infection in women: a phase 3, double-blind, randomized, placebo-controlled trial in Ghana,” PLoS One, vol. 2, no. 12, article e1312, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  57. C. K. Mauck, R. G. Freziers, T. L. Walsh, K. Peacock, J. L. Schwartz, and M. M. Callahan, “Noncomparative contraceptive efficacy of cellulose sulfate gel,” Obstetrics and Gynecology, vol. 111, no. 3, pp. 739–746, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  58. V. Halpern, F. Ogunsola, O. Obunge et al., “Effectiveness of cellulose sulfate vaginal gel for the prevention of HIV infection: results of a phase III trial in Nigeria,” PLoS One, vol. 3, no. 11, article e3784, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  59. S. Skoler-Karpoff, G. Ramjee, K. Ahmed et al., “Efficacy of Carraguard for prevention of HIV infection in women in South Africa: a randomised, double-blind, placebo-controlled trial,” The Lancet, vol. 372, no. 9654, pp. 1977–1987, 2008. View at Publisher · View at Google Scholar · View at Scopus
  60. S. McCormack, G. Ramjee, A. Kamali et al., “PRO2000 vaginal gel for prevention of HIV-1 infection (Microbicides Development Programme 301): a phase 3, randomised, double-blind, parallel-group trial,” The Lancet, vol. 376, no. 9749, pp. 1329–1337, 2010. View at Publisher · View at Google Scholar · View at Scopus
  61. L. Van Damme, R. Govinden, F. M. Mirembe et al., “Lack of effectiveness of cellulose sulfate gel for the prevention of vaginal HIV transmission,” The New England Journal of Medicine, vol. 359, no. 5, pp. 463–472, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  62. S. S. Abdool Karim, B. A. Richardson, G. Ramjee et al., “Safety and effectiveness of BufferGel and 0.5% PRO2000 gel for the prevention of HIV infection in women,” AIDS, vol. 25, no. 7, pp. 957–966, 2011. View at Publisher · View at Google Scholar · View at PubMed
  63. S. S. Olmsted, N. H. Dubin, R. A. Cone, and T. R. Moench, “The rate at which human sperm are immobilized and killed by mild acidity,” Fertility and Sterility, vol. 73, no. 4, pp. 687–693, 2000. View at Publisher · View at Google Scholar · View at Scopus
  64. A. E. Burke, K. Barnhart, J. T. Jensen et al., “Contraceptive efficacy, acceptability, and safety of C31G and nonoxynol-9 spermicidal gels: a randomized controlled trial,” Obstetrics & Gynecology, vol. 116, no. 6, pp. 1265–1273, 2010. View at Google Scholar
  65. T. Moench, J. Baker, and R. Cone, BufferGel is an Active Spermicide in the Standardized Postcoital Test, Microbicides, Alexandria, VA, USA, 2000.
  66. S. Garg, R. A. Anderson, C. J. Chany II et al., “Properties of a new acid-buffering bioadhesive vaginal formulation (ACIDFORM),” Contraception, vol. 64, no. 1, pp. 67–75, 2001. View at Publisher · View at Google Scholar
  67. E. Amaral, A. Perdigao, M. H. Souza, C. Mauck, D. Waller, L. Zaneveld et al., “Postcoital testing after the use of a bio-adhesive acid buffering gel (ACIDFORM) and a 2% nonoxynol-9 product,” Contraception, vol. 70, no. 6, pp. 492–497, 2004. View at Publisher · View at Google Scholar · View at PubMed
  68. L. M. Hughes, R. Griffith, and R. J. Aitken, “The search for a topical dual action spermicide/microbicide,” Current Medicinal Chemistry, vol. 14, no. 7, pp. 775–786, 2007. View at Publisher · View at Google Scholar
  69. A. Zairi, A. Belaid, A. Gahbiche, and K. Hani, “Spermicidal activity of dermaseptins,” Contraception, vol. 72, no. 6, pp. 447–453, 2005. View at Publisher · View at Google Scholar · View at PubMed
  70. A. Belaid, M. Aouni, R. Khelifa, A. Trabelsi, M. Jemmali, and K. Hani, “In vitro antiviral activity of dermaseptins against herpes simplex virus type 1,” Journal of Medical Virology, vol. 66, no. 2, pp. 229–234, 2002. View at Publisher · View at Google Scholar · View at PubMed
  71. K. V. R. Reddy, S. K. Shahani, and P. K. Meherji, “Spermicidal activity of magainins: in vitro and in vivo studies,” Contraception, vol. 53, no. 4, pp. 205–210, 1996. View at Publisher · View at Google Scholar
  72. O. J. D'Cruz and F. M. Uckun, “Dawn of non-nucleoside inhibitor-based anti-HIV microbicides,” Journal of Antimicrobial Chemotherapy, vol. 57, no. 3, pp. 411–423, 2006. View at Publisher · View at Google Scholar · View at PubMed
  73. H. K. Agarwal, A. Kumar, G. F. Doncel, and K. Parang, “Synthesis, antiviral and contraceptive activities of nucleoside-sodium cellulose sulfate acetate and succinate conjugates,” Bioorganic and Medicinal Chemistry Letters, vol. 20, no. 23, pp. 6993–6997, 2010. View at Publisher · View at Google Scholar · View at PubMed
  74. Q. A. Karim, S. S. A. Karim, J. A. Frohlich et al., “Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women,” Science Express, vol. 329, no. 5996, pp. 1168–1174, 2010. View at Publisher · View at Google Scholar · View at PubMed
  75. H. Weiss, “Epidemiology of herpes simplex virus type 2 infection in the developing world,” Herpes, vol. 11, supplement 1, pp. 24A–35A, 2004. View at Google Scholar
  76. M. John, M. J. Keller, E. H. Fam et al., “Cervicovaginal secretions contribute to innate resistance to herpes simplex virus infection,” Journal of Infectious Diseases, vol. 192, no. 10, pp. 1731–1740, 2005. View at Publisher · View at Google Scholar · View at PubMed
  77. E. E. Freeman, H. A. Weiss, J. R. Glynn, P. L. Cross, J. A. Whitworth, and R. J. Hayes, “Herpes simplex virus 2 infection increases HIV acquisition in men and women: systematic review and meta-analysis of longitudinal studies,” AIDS, vol. 20, no. 1, pp. 73–83, 2006. View at Google Scholar
  78. A. Wald and K. Link, “Risk of human immunodeficiency virus infection in herpes simplex virus type 2-seropositive persons: a meta-analysis,” Journal of Infectious Diseases, vol. 185, no. 1, pp. 45–52, 2002. View at Publisher · View at Google Scholar · View at PubMed
  79. D. Watson-Jones, H. A. Weiss, M. Rusizoka et al., “Effect of herpes simplex suppression on incidence of HIV among women in Tanzania,” The New England Journal of Medicine, vol. 358, no. 15, pp. 1560–1571, 2008. View at Publisher · View at Google Scholar · View at PubMed
  80. C. Celum, A. Wald, J. Hughes et al., “Effect of aciclovir on HIV-1 acquisition in herpes simplex virus 2 seropositive women and men who have sex with men: a randomised, double-blind, placebo-controlled trial,” The Lancet, vol. 371, no. 9630, pp. 2109–2119, 2008. View at Publisher · View at Google Scholar
  81. C. Celum, A. Wald, J. R. Lingappa et al., “Acyclovir and transmission of HIV-1 from persons infected with HIV-1 and HSV-2,” The New England Journal of Medicine, vol. 362, no. 5, pp. 427–439, 2010. View at Publisher · View at Google Scholar · View at PubMed
  82. J. Zhu, F. Hladik, A. Woodward et al., “Persistence of HIV-1 receptor-positive cells after HSV-2 reactivation is a potential mechanism for increased HIV-1 acquisition,” Nature Medicine, vol. 15, no. 8, pp. 886–892, 2009. View at Publisher · View at Google Scholar · View at PubMed
  83. J. Zhu, D. M. Koelle, J. Cao et al., “Virus-specific CD8+ T cells accumulate near sensory nerve endings in genital skin during subclinical HSV-2 reactivation,” Journal of Experimental Medicine, vol. 204, no. 3, pp. 595–603, 2007. View at Publisher · View at Google Scholar · View at PubMed
  84. R. D. Feigin and J. D. Cherry, Eds., Textbook of Pediatric Infectious Diseases, Elsevier, Sydney, Australia, 1998.
  85. R. B. Van Dyke, J. D. Connor, C. Wyborny, M. Hintz, and R. E. Keeney, “Pharmacokinetics of orally administered acyclovir in patients with herpes progenitalis,” American Journal of Medicine, vol. 73, no. 1 A, pp. 172–175, 1982. View at Google Scholar
  86. R. Gupta, E. L. Hill, D. McClernon et al., “Acyclovir sensitivity of sequential herpes simplex virus type 2 isolates from the genital mucosa of immunocompetent women,” Journal of Infectious Diseases, vol. 192, no. 6, pp. 1102–1107, 2005. View at Publisher · View at Google Scholar · View at PubMed
  87. A. D. M. Kashuba, S. S. A. Karim, E. Kraft, N. White, S. Sibeko, L. Werner et al., Do Systemic and Genital tract Tenofovir Concentrations Predict HIV Seroconversion in the CAPRISA 004 Tenofovir Gel Trial?AIDS, Vienna, Austria, 2010.
  88. C. B. Buck, C. D. Thompson, J. N. Roberts, M. Muller, D. R. Lowy, and J. T. Schiller, “Carrageenan is a potent inhibitor of papillomavirus infection,” PLoS Pathogens, vol. 2, no. 7, article e69, 2006. View at Publisher · View at Google Scholar · View at PubMed
  89. J. Kenney, M. Aravantinou, R. Singer et al., “Antiretroviral/zinc combination gel provides 24 hours of complete protection against vaginal SHIV infection in macaques,” PLoS One, vol. 6, no. 1, p. e15835, 2011. View at Google Scholar
  90. Y. Haraguchi, H. Sakurai, S. Hussain, B. M. Anner, and H. Hoshino, “Inhibition of HIV-1 infection by zinc group metal compounds,” Antiviral Research, vol. 43, no. 2, pp. 123–133, 1999. View at Publisher · View at Google Scholar
  91. G. Kumel, S. Schrader, H. Zentgraf, H. Daus, and M. Brendel, “The mechanism of the antiherpetic activity of zinc sulphate,” Journal of General Virology, vol. 71, part 12, pp. 2989–2997, 1990. View at Google Scholar
  92. M. Arens and S. Travis, “Zinc salts inactivate clinical isolates of herpes simplex virus in vitro,” Journal of Clinical Microbiology, vol. 38, no. 5, pp. 1758–1762, 2000. View at Google Scholar
  93. F. G. Burton, W. E. Skiens, and G. W. Duncan, “Low-level, progestogen-releasing vaginal contraceptive devices,” Contraception, vol. 19, no. 5, pp. 507–516, 1979. View at Google Scholar
  94. B. L. Xiao, X. L. Zhang, and D. D. Feng, “Pharmacokinetic and pharmacodynamic studies of vaginal rings releasing low-dose levonorgestrel,” Contraception, vol. 32, no. 5, pp. 455–471, 1985. View at Google Scholar
  95. S. Koetsawang, G. Ji, U. Krishna et al., “Microdose intravaginal levonorgestrel contraception: a multicentre clinical trial. I. Contraceptive efficacy and side effects. world health organization. Task force on long-acting systemic agents for fertility regulation,” Contraception, vol. 41, no. 2, pp. 105–124, 1990. View at Google Scholar
  96. S. Koetsawang, G. Ji, U. Krishna et al., “Microdose intravaginal levonorgestrel contraception: a multicentre clinical trial. IV. Bleeding patterns. world health organization. Task force on long-acting systemic agents for fertility regulation,” Contraception, vol. 41, no. 2, pp. 151–167, 1990. View at Google Scholar
  97. S. Koetsawang, G. Ji, U. Krishna et al., “Microdose intravaginal levonorgestrel contraception: a multicentre clinical trial. II. Expulsions and removals. world health organization. Task force on long-acting systemic agents for fertility regulation,” Contraception, vol. 41, no. 2, pp. 125–141, 1990. View at Google Scholar
  98. T. J. Johnson, K. M. Gupta, J. Fabian, T. H. Albright, and P. F. Kiser, “Segmented polyurethane intravaginal rings for the sustained combined delivery of antiretroviral agents dapivirine and tenofovir,” European Journal of Pharmaceutical Sciences, vol. 39, no. 4, pp. 203–212, 2010. View at Google Scholar
  99. A. Nel, S. Smythe, K. Young et al., “Safety and pharmacokinetics of dapivirine delivery from matrix and reservoir intravaginal rings to HIV-negative women,” Journal of Acquired Immune Deficiency Syndromes, vol. 51, no. 4, pp. 416–423, 2009. View at Publisher · View at Google Scholar
  100. J. Romano, B. Variano, P. Coplan et al., “Safety and availability of dapivirine (TMC120) delivered from an intravaginal ring,” AIDS Research and Human Retroviruses, vol. 25, no. 5, pp. 483–488, 2009. View at Publisher · View at Google Scholar · View at PubMed
  101. K. M. Gupta, S. M. Pearce, A. E. Poursaid et al., “Polyurethane intravaginal ring for controlled delivery of dapivirine, a nonnucleoside reverse transcriptase inhibitor of HIV-1,” Journal of Pharmaceutical Sciences, vol. 97, no. 10, pp. 4228–4239, 2008. View at Publisher · View at Google Scholar · View at PubMed
  102. P. Fletcher, S. Harman, H. Azijn et al., “Inhibition of human immunodeficiency virus type 1 infection by the candidate microbicide dapivirine, a nonnucleoside reverse transcriptase inhibitor,” Antimicrobial Agents and Chemotherapy, vol. 53, no. 2, pp. 487–495, 2009. View at Publisher · View at Google Scholar · View at PubMed
  103. A. M. Nel, P. Coplan, S. C. Smythe et al., “Pharmacokinetic assessment of dapivirine vaginal microbicide gel in healthy, HIV-negative women,” AIDS Research and Human Retroviruses, vol. 26, no. 11, pp. 1181–1190, 2010. View at Publisher · View at Google Scholar · View at PubMed
  104. A. M. Nel, S. C. Smythe, S. Habibi, P. E. Kaptur, and J. W. Romano, “Pharmacokinetics of 2 dapivirine vaginal microbicide gels and their safety Vs. Hydroxyethyl cellulose-based universal placebo gel,” Journal of Acquired Immune Deficiency Syndromes, vol. 55, no. 2, pp. 161–169, 2010. View at Publisher · View at Google Scholar · View at PubMed
  105. Coalition Advancing Multipurpose Innovations (CAMI), CAMI.org. Microbicides and Devices Matrix, 2011.
  106. A. R. Thurman, A. E. C. Holden, R. N. Shain, S. Perdue, and J. M. Piper, “Effect of acculturation on the acceptability of potential microbicides and sexual risk-taking,” Sexually Transmitted Diseases, vol. 36, no. 6, pp. 387–394, 2009. View at Publisher · View at Google Scholar · View at PubMed